Langan, SM; Abuabara, K; Henrickson, SE; Hoffstad, O; Margolis, DJ; (2017) Increased risk of cutaneous and systemic infections in atopic dermatitis - A cohort study. The Journal of investigative dermatology. ISSN 0022-202X DOI: https://doi.org/10.1016/j.jid.2017.01.030

Downloaded from: http://researchonline.lshtm.ac.uk/3515726/

DOI: https://doi.org/10.1016/j.jid.2017.01.030

Usage Guidelines:

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Increased Risk of Cutaneous and Systemic Infections in Atopic Dermatitis—A Cohort Study


TO THE EDITOR

Atopic dermatitis (AD, also known as atopic eczema or eczema), is characterized by skin barrier and immunologic dysfunction. Viral and bacterial superinfection of cutaneous lesions, including eczema herpeticum and Staphylococcus aureus in patients with severe disease is well documented (Ong and Leung, 2016; Weidinger and Novak, 2016). Whether the general population of patients with AD has an increased risk of these and other types of infections because of an impaired skin barrier and/or immunologic dysfunction is unclear.

A recent meta-analysis of genomewide association studies identified mutations in genes thought to play roles in the regulation of innate and adaptive immunity, in addition to established barrier function susceptibility loci such as filaggrin (Paternoster et al., 2015). Investigations of skin physiology suggest that differences in barrier function are identifiable very early in infancy and are highly predictive of the development of AD (Kelleher et al., 2015). We therefore hypothesized that individuals who develop AD are at increased risk of infections because of underlying genetically influenced immune and barrier dysfunction. The objective of our study was to determine if there was an association between AD and multiple common cutaneous and noncutaneous infections.

We performed a cohort study using The Health Improvement Network, a medical records database that is representative of the UK general population (Seminaara et al., 2010). Ethics approval for this study was obtained from The Health Improvement Network Scientific Review Committee and the University of Pennsylvania Institutional Review Board. We included 3,112,617 individuals registered before age 18 years who were followed for a mean of 13.7 years (95% confidence interval = 13.6, 13.7). We identified subjects with AD based on the presence of at least one of any of the following diagnostic codes on two different visits, as is common practice in studies of chronic conditions using electronic health data (Herrett et al., 2010): atopic dermatitis and related conditions (M11.00), atopic dermatitis/AD (M111.00), and atopic dermatitis not otherwise specified (M11z.00). The prevalence of AD was 14.4% (95% confidence interval = 14.4–14.4).

We examined the prevalence of multiple common cutaneous and noncutaneous infections (warts, dermatophyte infection, impetigo, molluscum contagiosum, otitis media, pneumonia, and streptococcal throat infection; codes available in Supplementary Table S1 online). We found that all of the infectious illnesses we had determined to test a priori were more prevalent in those with AD. Using multilevel mixed-effects logistic regression, we examined the odds of each infectious outcome at any time point and found that the strength of association for cutaneous infections varied from a 55% increased odds of impetigo to a 3-fold increased odds of...
molluscum contagiosum after adjusting for sex, age, time of observation, and practice. Associations with non-cutaneous infections varied from 27% increased odds of streptococcal throat infections to a 2-fold increase in otitis media (Table 1).

We performed sensitivity analyses exploring the definition of AD. When we estimated the association with a longer list of less-specific dermatitis codes (see Supplementary Table S1), we found that most associations were diminished. When we estimated the association with a more narrow designation, AD plus asthma or seasonal rhinitis, the magnitude of most of the associations increased. This highlighted a potential link between underlying immune dysfunction in atopic disease and increased susceptibility to infection.

Prior publications have found higher rates of infections among patients with AD, but most are from clinical populations, and therefore are likely to represent the more severe end of the AD spectrum (Beck et al., 2009; Peng et al., 2007), or are based on patient self-report, and therefore may be subject to recall and misclassification biases (Silverberg and Silverberg, 2014; Strom and Silverberg, 2016). Indirect evidence also comes from multiple studies that show an association between antibiotic use in early life and AD (Schmitt and Weidinger, 2014; Tsakok et al., 2013).

Strengths of this study include physician-confirmed diagnoses and a large longitudinal population-based sample. A number of potential limitations also warrant discussion. Our finding of an increased risk of cutaneous infections could be due to ascertainment bias (i.e., individuals with AD are more likely to have their skin checked and have skin conditions diagnosed). Although it is less likely that AD patients would have differential recording of systemic infections such as otitis or pneumonia, there may be a lower threshold for diagnosis or treatment of upper respiratory infections among patients with comorbid asthma, given the concern for asthma exacerbations with viral illness. Moreover, patients with chronic conditions like AD may be more likely to seek care. Nonetheless, our findings are important from a resource planning perspective; additional research is needed to understand the causal relationship between AD and infections. Finally, because AD can have a heterogeneous presentation, diagnosis may occasionally require specialist care, and we did not have access to dermatologist records. However, we believe our reliance on general practice physician records is reasonable in this context given that the vast majority (97%) of AD in the UK is treated in primary care (Emerson et al., 1998; Schofield, 2009).

We did not have detailed data about disease severity, flares, or timing of treatment use. Future studies examining whether there is a temporal association between these factors and infections could provide clinically useful prognostic information. Additionally, information on the timing of treatment use relative to infections could help establish whether specific treatment improves barrier function and reduces infection risk or whether immunosuppressive treatment increases infection risk. Because we studied the risk of infection at any time

Table 1. Prevalence and risk of infectious outcomes among those with AD compared with those without AD

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall Prevalence (n = 3,112,617)</th>
<th>Prevalence among Those with AD (n = 448,311)</th>
<th>Primary Analysis: Risk of Infectious Outcome Ever Using Different Exposure Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n % (95% CI)</td>
<td>n % (95% CI)</td>
<td>Crude</td>
</tr>
<tr>
<td>Cutaneous infections</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutaneous warts</td>
<td>285,011 (9.12) 9.12–9.19</td>
<td>72,681 (16.21) 16.10–16.32</td>
<td>2.23 (2.21–2.25) 1.98 (1.96–2.00) 1.50 (1.48–1.53) 2.91 (2.87–2.95)</td>
</tr>
<tr>
<td>Dermatophyte infection</td>
<td>24,693 (0.79) 0.78–0.80</td>
<td>7,899 (1.76) 1.72–1.80</td>
<td>2.83 (2.75–2.90) 2.54 (2.47–2.61) 2.14 (2.02–2.26) 3.56 (3.44–3.69)</td>
</tr>
<tr>
<td>Herpes simplex virus</td>
<td>65,027 (2.09) 2.07–2.10</td>
<td>18,461 (4.11) 4.06–4.18</td>
<td>2.41 (2.37–2.46) 2.08 (2.04–2.12) 1.81 (1.75–1.88) 3.26 (3.19–3.34)</td>
</tr>
<tr>
<td>Impetigo</td>
<td>21,467 (0.69) 0.68–0.70</td>
<td>7,899 (1.76) 1.72–1.80</td>
<td>3.50 (3.41–3.60) 1.55 (1.47–1.64) 2.06 (1.96–2.18) 3.82 (3.69–3.96)</td>
</tr>
<tr>
<td>Molluscum contagiosum</td>
<td>118,325 (3.80) 3.78–3.82</td>
<td>43,997 (9.81) 9.73–9.90</td>
<td>3.79 (3.74–3.84) 3.11 (3.07–3.14) 1.82 (1.78–1.86) 3.50 (3.44–3.56)</td>
</tr>
<tr>
<td>Systemic infections</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Otitis media</td>
<td>744,512 (23.93) 23.87–23.97</td>
<td>192,112 (42.85) 42.71–43.00</td>
<td>2.87 (2.85–2.88) 2.24 (2.22–2.25) 1.74 (1.72–1.76) 3.43 (3.40–3.47)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>69,880 (2.24) 2.22–2.26</td>
<td>17,087 (3.81) 3.76–3.87</td>
<td>1.96 (1.93–1.99) 1.27 (1.23–1.31) 1.48 (1.44–1.53) 2.76 (2.69–2.82)</td>
</tr>
<tr>
<td>Streptococcal throat infection</td>
<td>18,271 (0.59) 0.58–0.59</td>
<td>4,558 (1.02) 0.99–1.05</td>
<td>1.98 (1.92–2.05) 1.34 (1.26–1.42) 1.38 (1.30–1.46) 2.72 (2.60–2.84)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; OR, odds ratio.

¹Adjusted for age at registration, sex, and time under observation. Physician practice included as a random effect in the model.
point (including before AD diagnosis and treatment), our results are unlikely to be confounded by immunosuppressive treatment use for AD. As noted, multiple studies have shown an association between AD and early-life antibiotic exposure, which provides support for our hypothesis that patients with AD are at an increased risk of infection even before AD diagnosis, and/or could indicate an effect of antibiotics on the development of AD (Schmitt and Weidinger, 2014; Tsakok et al., 2013). Additional work is needed to determine whether antibiotic treatment plays a causal role in the development of AD.

In summary, we found increased risks of all infectious outcomes examined, which include both cutaneous and noncutaneous infections caused by bacteria, viruses, and fungi. This observation raises numerous questions about the nature of immunological defects in AD. One study found that subjects with AD in whom eczema herpeticum develops have more severe T helper type 2 cell-polarized disease, more atopic comorbidities, and more cutaneous infections (Beck et al., 2009). Our study adds epidemiologic evidence suggesting that AD patients may additionally be at risk of noncutaneous infections. A significant body of functional and genotype/phenotype data has been developed for filaggrin (McAleeer and Irvine, 2013), and there is a need for similar work linking immunological defects to clinical phenotypes.

Determining if individuals with AD are at increased risk of infections is important to guide the development of screening and prevention programs to reduce the morbidity associated with AD. Moreover, a baseline understanding of infectious risk is particularly important in the context of the introduction of the many new biologic therapies now in the pipeline for AD.

CONFLICT OF INTEREST
DJM is on separate data safety monitoring boards for Astellas, Janssen, Regeneron/Sanofi, and GlaxoSmithKline; the remaining authors state no conflict of interest.

ACKNOWLEDGMENTS
This work was supported by an NIH Clinician Scientist Fellowship (to SML, grant number NIH/CS/010/014) and a Wellcome Senior Clinical Fellowship in Science (205039/Z/16/Z). The funders had no role in study design, data collection, and analysis; decision to publish; or preparation of the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the UK Department of Health. This article presents independent research funded in part by the National Institute for Health Research (NIHR).

This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI grant number UL1 TR000004; the dermatology Foundation (KA); the Amos Medical Faculty Development Program (KA); and NIH T32 27207-257020416 (SH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Sinéad M. Langan1,5,*
Katrina Abuabara2,5
Sarah E. Henrickson3
Ole Hofstad4
and David J. Margolis4

1Faculty of Epidemiology & Population Health, London School of Hygiene and Tropical Medicine, London, UK; 2Program for Clinical Research, Department of Dermatology, University of California San Francisco (UCSF), San Francisco, California, USA; 3The Children’s Hospital of Philadelphia, Division of Allergy Immunology and Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; and 4Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA

*These authors contributed equally to this study. Corresponding author e-mail: sinead.langan@lsh tm.ac.uk

SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at www.jidonline.org, and at http://dx.doi.org/10.1016/j.jid.2017.01.030.

REFERENCES
Schofield JK, Grindlay D, Williams HC. Skin conditions in the UK: a health care needs assessment. Nottingham, UK: Center of Evidence Based Dermatology, University of Nottingham; 2009.

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/